Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma
| Autor: | Marie Brevet, Nicolas Girard, Marc Barritault, Jean-Michel Maury, Pierre Serra, Françoise Thivolet-Béjui, Nathalie Ebran, Arthur Petat, Lara Chalabreysse, Gérard Milano |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine Cancer Research Lung Neoplasms Adenocarcinoma of Lung B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine PD-L1 Biomarkers Tumor medicine Humans Clinical significance Survival analysis Aged Retrospective Studies Aged 80 and over Tissue microarray Lung biology business.industry Middle Aged medicine.disease Immunohistochemistry Survival Analysis Genes ras 030104 developmental biology medicine.anatomical_structure Oncology Tissue Array Analysis 030220 oncology & carcinogenesis Mutation biology.protein Cancer research Adenocarcinoma Female Tumor Suppressor Protein p53 Antibody business |
| Zdroj: | Lung Cancer. 118:62-68 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2018.02.005 |
| Popis: | Introduction The systematic assessment of anti-programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) in lung adenocarcinomas is becoming standard practice. However, the assessment of PD-L1 expression on small tissue specimens needs to be evaluated and the association with other features more thoroughly analyzed. Methods This retrospective single center study evaluated the immunohistochemical expression of the SP263 anti-PD-L1 antibody on tissue microarrays (TMA) of 152 surgically resected lung adenocarcinomas, using a 25% positivity threshold. The positive cases and 50 randomly chosen negative cases in tissue microarray (TMA) were reassessed on whole tissue sections. The results were correlated to clinical, histopathological and to molecular data obtained through the screening of 214 mutations in 26 genes (LungCarta panel, Agena Biosciences). Results Among 152 primary lung adenocarcinomas, 19 cases (13%) showed PD-L1 expression. The agreement between TMA and whole tissue sections was 89%, specificity was 97%. PD-L1 expression was correlated to RAS mutations (p = .04), RAS/TP53 co-mutations (p = .01) and to the solid or acinar subtype (p = .048). Conclusions With the SP263 PD-L1 antibody, small samples appear as a reliable means to evaluate the PD-L1 status in lung adenocarcinoma. The association between PD-L1 expression and RAS/TP53 mutations may have clinical relevance to predict the efficacy of PD-1/PD-L1 immune checkpoints inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect